{"title":"在接受克拉德滨和单克隆抗体治疗的高活性多发性硬化症患者中，无疾病活动性-3的证据。","authors":"Ricardo Alonso, Magdalena Casas, Luciana Lazaro, Nora Fernandez Liguori, Cecilia Pita, Leila Cohen, Juan Ignacio Rojas, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano, Marcos Burgos, Carlos Vrech, Raul Piedrabuena, Lopez Pablo, Norma Deri, Geraldine Luetic, Jimena Miguez, Mariela Cabrera, Alejandra Martinez, Gisela Zanga, Verónica Tkachuk, Santiago Tizio, Edgar Carnero Contentti, Eduardo Knorre, Felisa Leguizamon, Carolina Mainella, Pedro Nofal, Susana Liwacki, Javier Hryb, Maria Menichini, Claudia Pestchanker, Marina Alonso, Orlando Garcea, Berenice Silva","doi":"10.1177/20552173231154712","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years.</p><p><strong>Methods: </strong>This retrospective cohort study based on Argentina Multiple Sclerosis patient registry (RelevarEM), includes highly active multiple sclerosis patients who received HETs.</p><p><strong>Results: </strong>In total, 254 (78.51%) achieved NEDA-3 at year 1 and 220 (68.12%) achieved NEDA-3 at year 2. Patients who achieved NEDA-3 at 2 years had a shorter duration of multiple sclerosis (<i>p</i> < 0.01) and a shorter time between first treatment and current treatment (<i>p</i> = 0.01). Early high-efficacy strategy patients reached NEDA-3 more frequently (<i>p</i> < 0.01). Being a naïve patient (odds ratio: 3.78, 95% confidence interval 1.50-9.86, <i>p</i> < 0.01) was an independent predictor to reach NEDA-3 at 2 years. No association was found between type of HETs and NEDA-3 at 2 years when adjusted for potential confounders (odds ratio: 1.73; 95% confidence interval 0.51-6.06, <i>p</i> 0.57).</p><p><strong>Conclusion: </strong>We found a high proportion of patients who achieved NEDA-3 at 1 and 2 years. Early high-efficacy strategy patients had a higher probability of achieving NEDA-3 at 2 years.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173231154712"},"PeriodicalIF":2.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/18/10.1177_20552173231154712.PMC9950613.pdf","citationCount":"0","resultStr":"{\"title\":\"Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.\",\"authors\":\"Ricardo Alonso, Magdalena Casas, Luciana Lazaro, Nora Fernandez Liguori, Cecilia Pita, Leila Cohen, Juan Ignacio Rojas, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano, Marcos Burgos, Carlos Vrech, Raul Piedrabuena, Lopez Pablo, Norma Deri, Geraldine Luetic, Jimena Miguez, Mariela Cabrera, Alejandra Martinez, Gisela Zanga, Verónica Tkachuk, Santiago Tizio, Edgar Carnero Contentti, Eduardo Knorre, Felisa Leguizamon, Carolina Mainella, Pedro Nofal, Susana Liwacki, Javier Hryb, Maria Menichini, Claudia Pestchanker, Marina Alonso, Orlando Garcea, Berenice Silva\",\"doi\":\"10.1177/20552173231154712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years.</p><p><strong>Methods: </strong>This retrospective cohort study based on Argentina Multiple Sclerosis patient registry (RelevarEM), includes highly active multiple sclerosis patients who received HETs.</p><p><strong>Results: </strong>In total, 254 (78.51%) achieved NEDA-3 at year 1 and 220 (68.12%) achieved NEDA-3 at year 2. Patients who achieved NEDA-3 at 2 years had a shorter duration of multiple sclerosis (<i>p</i> < 0.01) and a shorter time between first treatment and current treatment (<i>p</i> = 0.01). Early high-efficacy strategy patients reached NEDA-3 more frequently (<i>p</i> < 0.01). Being a naïve patient (odds ratio: 3.78, 95% confidence interval 1.50-9.86, <i>p</i> < 0.01) was an independent predictor to reach NEDA-3 at 2 years. No association was found between type of HETs and NEDA-3 at 2 years when adjusted for potential confounders (odds ratio: 1.73; 95% confidence interval 0.51-6.06, <i>p</i> 0.57).</p><p><strong>Conclusion: </strong>We found a high proportion of patients who achieved NEDA-3 at 1 and 2 years. Early high-efficacy strategy patients had a higher probability of achieving NEDA-3 at 2 years.</p>\",\"PeriodicalId\":18961,\"journal\":{\"name\":\"Multiple Sclerosis Journal - Experimental, Translational and Clinical\",\"volume\":\"9 1\",\"pages\":\"20552173231154712\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/18/10.1177_20552173231154712.PMC9950613.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple Sclerosis Journal - Experimental, Translational and Clinical\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20552173231154712\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20552173231154712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:我们的目的是确定在高效治疗(HETs)下，在1年和2年达到无疾病活动证据3 (NEDA-3)的高活性多发性硬化症患者的比例，并确定在2年未能达到无疾病活动证据3的相关因素。方法:本回顾性队列研究基于阿根廷多发性硬化症患者登记处(RelevarEM)，包括接受HETs治疗的高度活跃的多发性硬化症患者。结果:254例(78.51%)患者在1年达到NEDA-3, 220例(68.12%)患者在2年达到NEDA-3。2年达到NEDA-3的患者多发性硬化症持续时间较短(p p = 0.01)。早期高效策略患者达到NEDA-3的频率更高(p < p < 0.57)。结论:我们发现在1年和2年达到NEDA-3的患者比例很高。早期高效策略患者在2年时达到NEDA-3的概率更高。
Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.
Background: We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years.
Methods: This retrospective cohort study based on Argentina Multiple Sclerosis patient registry (RelevarEM), includes highly active multiple sclerosis patients who received HETs.
Results: In total, 254 (78.51%) achieved NEDA-3 at year 1 and 220 (68.12%) achieved NEDA-3 at year 2. Patients who achieved NEDA-3 at 2 years had a shorter duration of multiple sclerosis (p < 0.01) and a shorter time between first treatment and current treatment (p = 0.01). Early high-efficacy strategy patients reached NEDA-3 more frequently (p < 0.01). Being a naïve patient (odds ratio: 3.78, 95% confidence interval 1.50-9.86, p < 0.01) was an independent predictor to reach NEDA-3 at 2 years. No association was found between type of HETs and NEDA-3 at 2 years when adjusted for potential confounders (odds ratio: 1.73; 95% confidence interval 0.51-6.06, p 0.57).
Conclusion: We found a high proportion of patients who achieved NEDA-3 at 1 and 2 years. Early high-efficacy strategy patients had a higher probability of achieving NEDA-3 at 2 years.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
